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ABSTRACT
EXPLORING THE ROLES OF HOST AND TUMOR CELL α4 AND α7
NICOTINIC ACETYLCHOLINE RECEPTORS IN LUNG CANCER
John Caleb Greenwell
1/30/2015
Lung cancer is the leading cause of cancer death in men and women
worldwide. Tobacco exposure represents the major risk factor. Nicotine, an
addictive plant alkaloid found in tobacco, has been demonstrated to stimulate
lung carcinoma cells directly via nicotinic acetylcholine receptors (nAChRs) that
trigger downstream signals capable of promoting lung cancer growth and
progression. Attention has been given to α7 nAChRs, while less is known
about α4 nAChRs. However, most studies evaluating these receptors relied on
chemical inhibitors notorious for their off-target effects. Consequently, the true
role of α4 and α7 nAChRs in lung cancer remains unclear. To address this, we
performed in vitro and in vivo studies using Lewis Lung Carcinoma (LLC) cells
silenced with shRNA for α4 or α7 nAChRs. As expected, nicotine stimulated the
proliferation of LLC cells in vitro. However, tumor cells treated with specific
inhibitors of α4 or α7 nAChRs independently, did not inhibit nicotine-induced
proliferation; inhibition of proliferation required that receptors be targeted
concomitantly with a broad-spectrum inhibitor. Similar observations were made
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when the receptors were silenced separately with shRNA; however cells showed
increased proliferation at baseline when silenced for nAChRs. In LLC cells
silenced for α4 nAChRs we observed fewer colonies on soft agar, decreased
migration, and decreased apoptosis in response to cisplatin, when compared to
untransfected cancer cells and cells transfected with control shRNA. Cells
silenced for α7 nAChRs did not differ from untransfected cancer cells or cells
transfected with control shRNA, with respect to colony formation, migration, and
apoptosis. In a lung cancer xenograft model, silencing of α4 and α7 nAChRs in
cancer cells resulted in no significant differences in tumor size, and did not alter
overall survival. While exploring the role of host cell receptors, no differences
were observed in tumor number or size in a spontaneous tumor formation model
in animals carrying KRAS and α7 nAChR mutations. In contrast, larger tumors
were observed in α7 nAChR knockout mice injected with wildtype LLCs. These
studies suggest differential roles for α4 and α7 nAChRs in murine lung
carcinoma cells, with α4 nAChRs having a predominant role in vitro. However,
studies performed in animals suggest that targeting these receptors
independently in tumor cells may not affect tumor progression in vivo, while
targeting host receptors may.
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INTRODUCTION

Lung cancer is the leading cause of cancer death in men and women in
the United States1. In 2015 alone, lung cancer is estimated to take the lives of
over 158,000 individuals, which represents 27% of all cancer deaths2. Lung
cancer has a dismal 17% five-year survival rate that has not changed
substantially over the past 35 years, despite the development of new surgical
procedures, and the use of new radio- and chemotherapeutic protocols3. This
underscores a desperate need for new strategies in prevention, early detection,
and treatment of this deadly disease. Tobacco use represents the major risk
factor and is responsible for 71% of global lung cancer deaths4. Tobacco smoke
is extremely complex, consisting of thousands of compounds, and over 60
carcinogens5. Several carcinogens, in particular, thought to be responsible for
lung cancer development and progression include the polycyclic aromatic
hydrocarbons and the nicotine-derived nitrosamines, N'-nitrosonornicotine (NNN)
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), among others. The
metabolites of these compounds cause mutations in vital genes such as Rb, p53,
and KRAS6. However, it was recently shown that expression of oncogenic KRAS
and knockdown of the tumor suppressor protein p53 were insufficient to confer a
full malignant phenotype in bronchial epithelial cells, suggesting that the role
these genes and their products play in lung cancer development may have been

1

overemphasized7. This, along with emerging data suggesting an important role of
the microenvironment in the etiology of many cancers, leads us to believe that
other factors are involved.
We have focused our attention on nicotine, a major plant alkaloid in
tobacco. Historically, nicotine was thought to only mediate smoking dependence
and addiction by working through reward centers in the brain to cause a release
of dopamine and a general sense of euphoria8. More recent data, however,
reveal that, even though nicotine may be unable to initiate oncogenic
transformation, it promotes cancer cell proliferation in vitro and may stimulate
tumor

progression9–11.

Nicotine

mediates

its

effects

through

nicotinic

acetylcholine receptors (nAChRs) by mimicking acetylcholine, the endogenous
ligand for these receptors12. NAChRs comprise a family of multimeric cation
channel proteins that act as central regulators of a vital network of excitatory and
inhibitory neurotransmitters that governs the function of all organs and cells in the
mammalian organism. They are located in the plasma membrane and can exist
as homo- or heteropentamers. Previously thought to exist only in the nervous
system and neuromuscular junctions, they are now recognized as being
universally expressed in mammalian cells, and in many cancers13. Upon ligand
binding in the alpha subunit, the receptors undergo conformational changes that
open the channel, allowing cations to rush down their concentration gradient,
resulting in depolarization of the plasma membrane and activation of intracellular
signal transduction pathways14.
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The link between nAChRs and lung cancer was recently strengthened by
studies identifying a common variant in the nAChR gene cluster on chromosome
15q25 with a predisposition to lung cancer15. This locus was found to account for
14% (attributable risk) of lung cancer cases. In tumor cells, activation of nAChR
signaling stimulates cell proliferation, tumor progression, and metastasis through
induction of the synthesis and release of growth, angiogenic, apoptotic, and
metastatic factors11.

However, both tumor cells and host cells of the tumor

microenvironment express several of these receptors and the true contribution of
distinct nAChRs in lung cancer remains unclear. Furthermore, studies evaluating
these receptors have relied on chemical inhibitors, which are notorious for their
off-target effects. Thus, the true role of distinct nAChRs in lung cancer remains
incompletely understood.
Here, we evaluate the relative contribution of α7 and α4 nAChRs in lung
cancer using Lewis Lung Carcinoma cells silenced for these receptors using
shRNA technology. Our data suggest that although these receptors play distinct
roles in several biological processes in tumor cells tested in vitro, with a
predominant role for α4 nAChRs, targeting them individually did not lead to
significant beneficial effects for the host in a rodent xenograft model. However,
in experiments performed in genetically engineered animals to test the role of
host cell α7 nAChRs, we observed larger tumor growth compared to wildtype
animals.

These studies underscore the need to carefully define the relative

contributions of these receptors, in both host and tumor cells, prior to the
development of interventions for treatment in humans.
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MATERIALS AND METHODS

Reagents and Cell Culture
Lewis Lung Carcinoma (LLC) cells were purchased from ATCC (CRL-1642;
ATCC, Rockville, MD) and grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals,
Lawrenceburg, GA), 50 IU/ml penicillin/ streptomycin, and 1 mg amphotericin
(Corning Cellgro) at 37 ºC in a humidified 5% CO2 incubator. The mouse nAChR
α4 or α7 subunit or control nontarget shRNA plasmid DNA constructs were
purchased from Sigma (St. Louis, MO). Polyclonal antibodies specific for α4
nAChR (SAB2100424) and α7 nAChR (AV13018) were purchased from Sigma
Aldrich (St. Louis, MO). Chemical antagonists were purchased from Tocris
Bioscience (Ellisville, MO). The Cell Titer-Glo® Luminescent Cell Viability Assay
and Caspase-Glo® 3/7 Assay were obtained from Promega (Madison, WI). Cell
transformation detection assay (colony formation) kit was obtained from Millipore
(Temecula, CA).

Silencing of α4 and α7 nAChRs with shRNA
LLC cells (2.3x107 cells/mL) were permanently transfected with 160 µg of
control, α4 or α7 shRNA plasmid DNA as previously described16. Briefly, cells
were harvested by trypsinization, washed, and resuspended in buffer containing
4

20 mM Hepes, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, and 6 mM dextrose
at pH 7.05. Afterwards, the cells were added to a 0.4-cm-gap cuvette containing
the shRNA plasmid DNA, and transfected with a Gene Pulser II electroporation
apparatus set at 390v and 500 mF (Bio-Rad, Hercules, CA). Cells were then
plated onto 75-mm2 tissue culture flasks. ShRNA-expressing cells were selected
by the addition of 5 µ g/ml puromycin antibiotic for a minimum of 2 weeks. To
obtain individual clones, cells were serially diluted into 96-well tissue culture
plates. Single colonies were then tested for nAChR levels by Western Blot
analysis.

Western Blot
Western blot analysis was performed on wildtype (WT) LLC cells and cells
transfected with control shRNA or shRNAs to α4 and α7 nAChRs as previously
described17. Protein (40-50 µg) was heated at 90 ºC for 5 minutes and briefly
centrifuged. Proteins were transferred onto nitrocellulose membranes using a
BioRad Trans-Blot® SD Semi-Dry Transfer Cell machine for 2 hours at 25V.
Blots were incubated overnight in 15mL conicals in 5mL 5% non-fat dry milk in
TBST at 4ºC with anti-α4 and/or anti-α7 nAChR (1:500) antibody, washed 3 times
for 10 minutes in TBST, and incubated with a secondary anti-rabbit IgG HRP
(1:20,000) for 1 hour at RT. Blots were again washed (3 x 10 minutes),
transferred to Amersham ECL Western Blotting Detection Reagents (GE
Healthcare, Little Chalfont, UK) for 1 minute and exposed to Genemate Blue
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Basic Autorad film (Bioexpress, Kaysville, UT) for up to 1 hour. Protein
densitometry was completed using GS-800 Calibrated Densitometer (Bio-rad).

Proliferation Assay
WT LLC cells and cells transfected with control shRNA or shRNAs
targeting α4 or α7 nAChRs (500 cells/well) were plated in white-walled, clearbottom 96-well plates and cultured with or without nicotine for 5 days in media
containing DMEM with 2% FBS and 25mM HEPES buffer. Media was replaced
every 2 days. Cell proliferation was evaluated using the Promega CellTiter-Glo®
Luminescent Cell Viability Assay (Madison, WI), in a Luminoskan Ascent
Luminometer (Beckman Coulter), according to the manufacturer’s instructions.
The CellTiter-Glo® Luminescent Cell Viability Assay is determines the number of
viable cells in culture based on the quantitation of the ATP present, which signals
the presence of metabolically active cells.

Migration Assay
Cells were grown to ~70% confluence in six-well plates in culture media
containing DMEM with 10% FBS. A sterile 1000-µl pipette tip was used to create
a scratch in 3 separate locations within each well. Media was aspirated and
pictures taken at 0 hours to measure the width of the unveiled area. Afterwards,
the media (5 mL) was replaced and cells were allowed to recover for 48 hours,
after which pictures were taken again to measure the covered area.
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Colony Formation Assay
A 0.8% base agar layer was prepared and added to an equal amount of
culture media (250 µL/12-/well). Plates were placed at 4ºC for at least 30 minutes
to allow base agar layer to gel. Top agar (0.4%) layer was prepared by mixing
0.8% solution with equal amount of culture media (DMEM). Plates were
incubated at 37ºC for 5 minutes prior to addition of cells (500/well) followed by
incubation for 21 days. Fresh media (500 µl/well) was added every 3-4 days,
after aspiration of old media. Afterwards, colonies were photographed and
quantified using a Beckman plate reader and cell quantification solution (OD 490
nM).

Apoptosis Assay
WT LLC cells and control and α4 and α7 nAChR shRNA-transfected LLC
cells (3x103) were plated in white-walled, clear-bottom 96-well plates and
cultured in DMEM with 10% FBS with or without 20 µM cisplatin for 24 hours.
Apoptosis was then evaluated using the Promega Caspase-Glo® 3/7 Assay
(Madison, WI), in a Luminoskan Ascent Luminometer (Beckman Coulter),
according to the manufacturer’s instructions. This assay works by providing a
luminogenic substrate (Z-DEVD- aminoluciferin) for caspases 3 and 7, that upon
cleavage, releases aminoluciferin, which then becomes a substrate for luciferase.
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Animal Studies
All mice used in this study were obtained from Jackson Laboratories. The
institutional animal care and use committee of the University of Louisville
approved all experiments. LLC cells were plated out 24 hours prior to injections
and were harvested at ~50% confluence to insure cells were in adequate growth
phase. LLC cells (5 × 105 /100 µl sterile PBS) stably transfected with control
non-target shRNA, α4 shRNA, or α7 shRNA were injected subcutaneously into
the hind flank of wildtype C57BL/6 mice. Afterwards, tumors were monitored and
measured weekly. A tumor size >15mm in any direction was considered the
endpoint, according to IACUC regulations. Animals were sacrificed and tissues
were harvested for analysis. For experiments using α7 nAChR KO mice, 5 ×
105 WT LLC cells/100 µl sterile PBS were injected subcutaneously into the hind
flank and followed as described above.

Animals lacking α7 nAChR and

expressing heterozygous mutations for KRAS were developed by breeding mice
heterozygous for α7 nAChR with mice heterozygous for KRAS. The double
heterozygous progeny were then bred for four generations to develop animals
lacking α7 nAChR and expressing heterozygous mutations for KRAS; mutations
were confirmed via PCR. These animals developed spontaneous tumors and
were sacrificed at 90 days at which time the lungs were harvested for analysis.

Histological Analysis
Animals were euthanized by exposure to carbon dioxide in a closed
chamber. Lungs were isolated and inflated at standard pressure, formalin-fixed,
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paraffin-embedded, and sectioned (6 µm) using a JUNG RM2055 microtome
(Leica, Buffalo Groce, IL). They were then transferred onto glass microslides for
histological analysis. Sections were deparaffinized, rehydrated, and stained with
hematoxylin and eosin (H&E) to evaluate lung tumors.

Analysis of Data
Means plus standard deviations of the mean were calculated for all
experimental values. Significance was assessed by using the Student's t test. All
experiments were repeated a minimum of 3 times with each sample group
containing a minimum number of 3. For survival distributions, the Log-rank test
and/or Wilcoxon test were used to determine significance.
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RESULTS

Nicotine stimulates LLC cell proliferation, but its mitogenic effects are not
affected by separate chemical inhibition of α7 or α4 nAChRs
Nicotine has been shown to stimulate lung carcinoma cell proliferation in
vitro18. To begin to identify key receptors mediating these effects, we exposed
WT LLC cells to nicotine and tested the effects of nAChR inhibitors. As presented
in Figure 1A-C, nicotine (50µg/mL) stimulated LLC cell proliferation. The
mitogenic effects of nicotine were decreased by a broad, non-specific nAChR
inhibitor, mecamylamine (Figure 1A). However, dihydro-β-erythroidine (DhβE), a
more specific inhibitor of α4 nAChRs had little effect (Figure 1B). MG624, a
more specific inhibitor of α7 nAChRs, also had no affect (Figure 1C).
Interestingly, we observed mild increases in proliferation in cells treated with
MG624 alone, suggesting a role for α7 nAChR in control of proliferation at
baseline in unstimulated cells.

LLC cells silenced for α4 nAChR show decreased migration, colony
formation, and apoptosis, while cells silenced for α7 nAChR do not
We transfected WT LLC cells with control shRNA (LLC/Consh) or shRNA
against α4 nAChR (clones LLC/α4CLA and LLC/α4CLB) or α7 nAChR (clones
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LLC/α7CLC and LLC/α7CLD). These clones were found to have less than ~75%
protein expression for α4 and α7 nAChRs, and these were used for further
studies (Figure 2A-2C, respectively). To ensure that the transfection procedure
by itself did not affect responsiveness to nicotine, LLC/Consh cells were exposed
to nicotine and treated with DhβE and MG624. Again, nicotine stimulated the
proliferation of cells transfected with control shRNA cells and, as before, DhβE
and MG624 did not affect the response dramatically (not shown).
We then examined the effect of α4 and α7 nAChR silencing on nicotineinduced LLC proliferation. As presented in Figure 3, proliferation was again
significantly increased in nicotine-treated LLC/UT (untransfected) and LLC/Consh
cells. Consistent with the findings related to the chemical inhibitors, silencing of
α4 or α7 nAChRs did not prevent-nicotine-induced proliferation. However, lack of
α4 and α7 nAChRs resulted in mild increases in proliferation of unstimulated
cells.
We next examined the role of α4 and α7 nAChRs in cellular migration.
Cells were grown to ~80% confluence, after which time, a wound was created
using a sterile 1 mL pipette tip. After 48 hours, only ~30% of the initial wound
area remained in LLC/UT and LLC/Consh cells (Figure 4A and 4B). In contrast,
after 48 hours, ~85% and ~75% of the initial wound area remained in the
LLC/α4CLA and LLC/α4CLB cells, respectively; LLC/α7CLC and LLC/α7CLD cells
showed no difference compared to controls.
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Figure 1

Figure 1. Role of nAChRs in nicotine-induced lung cancer cell proliferation
(A) WT LLC cells were cultured with increasing concentrations of mecamylamine
in the presence or absence of nicotine (50 µg/mL) for 5 days. Fresh media
containing nicotine was added every 2 days. The number of viable cells was
detected using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega)
Mecamylamine significantly decreased nicotine-induced proliferation at 100 µM.
(B) WT LLC cells were cultured with increasing concentrations of dhβe in the
presence or absence of nicotine (50 µg/mL) for 5 days and treated and
processed as described above. Note that dhβe had no effect on nicotine-induced
proliferation. (C) WT LLC cells were cultured with increasing concentrations of
MG624 in the presence or absence of nicotine (50 µg/mL) for 5 days and treated
and processed as described above. MG624 mildly increased baseline
proliferation in a dose-dependent manner in untreated cells, and had no effect on
nicotine-induced proliferation. All data are depicted as means +/- SD. Asterisks
indicate a significant difference from untreated control.
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Figure 2

Figure 2. Characterization of LLC cells silenced for nAChRs
After transfection with shRNA targeting nAChRs, LLC cells were grown to ~7080% confluency and were harvested via cell scraping in PBS. No trypsin was
used. Total protein (40 µg) was isolated from LLC/UT, LLC/Consh, LLC/α4CLA,
LLC/α4CLB, LLC/α7CLC, or LLC/α7CLD cells and Western Blot analysis for α4 (A,B)
and α7 (C) was performed. Anti-GAPDH antibody was used to control for gel
loading. UT = untransfected cells. Brain = positive control. Clones labeled A and
B were chosen for α4 knockdown, whiles clones labeled C and D were chosen
for α7 knockdown.
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Figure 3

Figure 3. Silencing of α4 and α7 nAChRs does not inhibit nicotine-induced
proliferation
Cells were cultured with or without nicotine (50 µg/mL) for 5 days. Fresh media
containing nicotine was added every 2 days. The number of viable cells was
detected using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega).
Nicotine significantly increased cellular proliferation in LLC/UT, LLC/Consh,
LLC/α4CLA, LLC/α4CLB, LLC/α7CLC, and LLC/α7CLD cells. At baseline, cells
silenced for α4 and α7 showed increased cell proliferation, but nicotine-induced
proliferation was unchanged.
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Figure 4

Figure 4. Migration is decreased in LLC cells silenced for α4 nAChR, but
not in cells silenced for α7 nAChR
(A) Control and nAChR-silenced LLC cells were grown to ~80% confluency in
six-well plates. Afterwards, a sterile 1000 µL pipette tip was used to create a
scratch in three separate locations. Media was then aspirated to remove floating
cells. DMEM (8mL) containing 10% FBS was then added and the cells were
allowed to recover for 48 hours. Wound sites were photographed at 0 hours and
48 hours. (B) Quantification of wound length in photographs was performed by
measuring the distance of the initial wound area in 3 separate locations at 48
hours, which was subtracted from the initial distance at time 0 hours.
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Next, we tested the effects of α4 nAChRs on colony formation on soft
agar. As depicted in Figure 5A, nicotine significantly increased the number of
colonies in LLC/UT and transfected cells. At baseline, overall colony formation
was reduced in cells silenced for the α4 nAChR, but the cells remained
responsive to nicotine. In contrast, cells silenced for α7 showed no difference in
colony number when compared to controls (Figure 5B).
Lastly, we examined the role of α4 and α7 nAChRs in drug-induced
apoptosis. As depicted in Figure 6, silencing of α4 nAChR significantly reduced
the amount of cisplatin-induced apoptosis when compared to LLC/UT cells, as
determined by caspase 3/7 activity (Figure 6A) and ATP (Figure 6B) levels, with
a greater effect noticed in LLC/α4CLA cells. Note that α4 nAChR silencing did not
affect the number of viable cells. Silencing of α7 nAChRs had no effect.

Mice injected subcutaneously with cancer cells silenced for α4 or α7
nAChR do not display changes in survival compared to controls
Having examined the properties of the α4 and α7 nAChR-silenced clones
in vitro, we proceeded to test their role in vivo. To this end, C57BL/6 mice were
injected subcutaneously with LLC/Consh cells, LLC/ α4sh (clones A and B) cells,
or LLC/ α7sh (clones C and D) cells. Tumor formation and size were followed for
up to 12 weeks. 73% of mice injected with LLC/Consh cells developed tumors
over the course of the experiment. In comparison, only 33.3% and 66.7% of the
mice injected with LLC/ α4sh cells (clones A and B, respectively) developed
tumors, but this difference was not statistically significant. There was also no
16

Figure 5

Figure 5. Colony formation is decreased in LLC cells silenced for α4
nAChR, but not in cells silenced for α7 nAChR
Control and nAChR-silenced LLC cells (500) were suspended in 0.4% top agar
layer and plated on a 0.8% base agar layer, which was prepared according to
Millipore’s instructions. After 12 hours, 500 µL DMEM was added. Media was
replaced every 3-4 days. Colonies were followed for 21 days and then counted.
(A) Colony formation was decreased in LLC/α4CLA and LLC/α4CLB cells compared
to LLC/Consh and LLC/UT cells, but nicotine stimulation was observed. (B) There
was no difference in colony number in LLC/α7CLC and LLC/α7CLD cells when
compared to controls at baseline, but nicotine stimulation was observed.
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Figure 6

Figure 6. Cisplatin-Induced death is decreased in LLC Cells silenced for α4
nAChR
Cells were cultured in complete DMEM containing 50 µM Cisplatin for 24 hours.
Caspase 3/7 activity was detected using the Caspase-Glo 3/7 Assay Kit
(Promega). Caspase 3/7 activity was decreased in LLC/α4CLA and LLC/α4CLB
cells compared to LLC/Consh cells (A). The number of viable cells was detected
using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega) (B). Cell
viability was increased ~4 fold in LLC/α4CLA and LLC/α4CLB cells compared to
LLC/UT cells in cisplatin-treated cells.
18

difference in tumor size or survival amongst the experimental groups (Figure
7A,B). Animals injected with α7 nAChR-silenced clones, also showed no
difference in tumor number or size, and did not display changes in survival when
compared to those injected with control clones (Figure 7C,D).

Role of host cell α7 nAChRs in lung cancer
To begin to investigate the role of host cell nAChRs, we injected WT LLC
cells into WT C57BL/6 and α7 nAChR knockout mice. As depicted in Figure 8A,
animals deficient in α7 nAChRs grew tumors faster compared to wildtype
animals, and thus displayed decreased survival between 20 and 30 days (8B).
By their very nature, xenograft models of lung cancer allow for the study of
tumor growth and metastasis, but not tumor development. To test this, we chose
to study animals with KRAS mutations, which spontaneously develop tumors.
KRAS mutations are relatively frequent in non-small cell lung cancer in
humans19. Animals with both KRAS mutations and α7 nAChR mutations were
sacrificed at 90 days to examine spontaneous tumor development. As presented
in Figure 9, no differences were noted between KRAS and KRAS/α7 nAChR
knockout animals with respect to tumor number or size in the lungs.
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Figure 7

Figure 7. Mice injected with LLC cells silenced for α4 nAChR demonstrate
no differences in tumor size compared to control, and do not show
differences in survival
(A,B) LLC/Consh (n=11), LLC/α4CLA (n=9), LLC/α4CLB (n=9) cells (5x105) were
injected into the hind flank of WT C57BL/6 mice. Tumor formation and size were
followed up to 12 weeks. A tumor size of ≥15mm in length or width was
established as the endpoint according to IACUC regulations. Mice were then
sacrificed and lungs harvested and processed for examination of metastases. No
differences were noted amongst groups when evaluating tumor size (A) or
survival (B).
(C,D) LLC/Consh (n=5), LLC/α7CLC (n=5) and LLC/α7CLD (n=4)
(5x105) cells were injected into the hind flank of WT C57BL/6 mice Tumor
formation and size were followed up to 12 weeks. A tumor size of ≥15mm in
length or width was established as the endpoint according to IACUC regulations.
Mice were then sacrificed and lungs harvested and processed for examination of
metastases. No differences were noted amongst groups when evaluating tumor
size (C) and survival (D).
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Figure 8

Figure 8. Tumor growth is increased α7 nAChR deficient animals
LLC/WT cells (1x106) were injected into the hind flank of WT C57BL/6 mice (n=8)
or α7 nAChR knockout mice (n=7). Tumor formation and size were followed up to
6 weeks. A tumor size of ≥15mm in length or width was established as the
endpoint according to IACUC regulations. Mice were then sacrificed and lungs
harvested and processed for examination of metastases. Larger tumors were
observed in α7 nAChR knockout mice (A), which led to decreased survival (B).

21

Figure 9

Figure 9. Spontaneous tumor development is unchanged in KRAS/α7
nAChR knockout mice when compared to KRAS mice
KRAS (n=5) and KRAS/α7 nAChR knockout mice (n=6) were sacrificed at 90
days and lungs harvested and processed for examination of tumors.
Representative PCR gel images shown for genotyping (A). Representative lung
tumor images shown at 1x and 4x (B). No differences in lung tumor number or
size were observed (C).
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DISCUSSION

It is well established that tobacco use is the number one risk factor for
development of lung cancer, which will take the lives of millions of people
worldwide this year4. Despite major increases in survival rates of many cancers,
little progress has been made in the treatment of lung cancer. Data, however, are
emerging showing important roles for nAChRs in cancer biology, which places
emphasis on the role of nicotine, an important component of tobacco and an
exogenous ligand for these receptors20. The mitogenic effects of nicotine are well
known and a number of investigators have shown that these effects can be
abolished by using chemical nAChR antagonists, such as α-bungarotoxin21–23.
However, results obtained from experiments using such antagonists must be
viewed with caution due to off-target effects. An important example is varenicline,
a prescription drug used for smoking cessation. The mechanism of action of
varenicline is reported to be through partial agonism of α4β2 nAChRs
receptors24, but recent data suggest that this agent also binds to α3- and α6containing nAChRs and displays full agonism on α7 nAChRs25. These off-target
effects make it difficult to examine the role of individual nAChRs when using such
chemicals. We thus used shRNA technology to knockdown a single, specific
nAChR subunit at a time, allowing for careful delineation of the roles of the
different receptors. We tested LLCs because of the extensive literature available
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using these cells to study lung cancer in models that allow their use in normal,
immunocompetant C57BL/6 mice.
First, we confirmed that nicotine exerted mitogenic effects on WT LLC
cells. Note that, as previously reported18, this effect was relatively small (~3040%), which is likely due to the fact that the cells were not starved prior to
stimulation as others have reported11,26. At least one group has shown that the
ability of nicotine to increase expression of Akt, Erk, and mTOR activation in
vitro, was largely dependent on the absence of serum which causes lower basal
levels of pathway activation27. Instead, the cells were cultured in 2% fetal bovine
serum, which we believe is more physiologically relevant. Although the most
robust effect was noted at the highest dose tested (276% increase over control),
we chose to use doses more physiologically relevant for further experiments. As
expected, based on the literature, we found that a non-specific nAChR chemical
inhibitor (e.g., mecamylamine) diminished nicotine-induced LLC cell proliferation,
although the effect was relatively small. However, more specific inhibitors
targeting α4 or α7 nAChRs independently did not inhibit nicotine-induced cell
proliferation, while the α7 nAChR antagonist had a small mitogenic effect at
higher doses. This lack of a significant inhibitory activity was confirmed in cells
silenced specifically for either the α4 or the α7 nAChR subunits. This may
suggest that nAChRs containing the α4 and α7 subunits play little role in
nicotine-induced proliferation, and that effects seen in other studies performed
using chemical antagonists were indeed due to off-target effects. On the other
hand, we believe it is more likely that nicotine-induced proliferation in LLC cells is
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not mediated by a single nAChR, but several, and that blocking one or the other
independently is not sufficient to completely inhibit proliferation. In other words,
both α4 and α7 nAChRs, and perhaps others, need to be targeted to inhibit
nicotine-induced cell proliferation. One interesting observation that remains
unexplained relates to the mild induction of proliferation observed in unstimulated
α7 nAChR-silenced cells. We have observed a similar effect in lung fibroblasts
(unpublished data); this seemingly paradoxical effect has been reported in the
literature in airway epithelial basal cells28. Our data suggest that α7 nAChRs
might restrain proliferation in unstimulated cells, while this effect is overcome in
cells lacking this receptor. This raises the possibility of multiple receptors
mediating these effects, but this requires further investigation.
In contrast to our observations regarding cell proliferation, we found that
cells silenced for α4 nAChRs, but not α7 nAChRs, showed reduced migration
and ability to form colonies on soft agar when compared to controls. Deficiency
of α4 nAChRs also resulted in resistance to cisplatin-induced apoptosis.
Having characterized the clones in vitro, we turned our attention to testing
the roles of these receptors in an in vivo model of lung cancer. For this, cells
silenced for α4 or α7 nAChR subunits were injected subcutaneously into
C57BL/6 mice. Mice injected with cells silenced for α4 nAChRs developed fewer
tumors, but this was not statistically significant. No differences were observed in
animals injected with control or α7 nAChR deficient cells. Tumor size was also
not different between groups.

Importantly, silencing α4 or α7 nAChRs

independently had no significant effect on the survival of animals. Note that
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tumor growth and progression (and animal survival) were tested in untreated
animals suggesting that these nAChRs play insignificant roles in tumor
progression in the absence of exogenous stimulation. Whether these receptors
play roles in tumor progression in the setting of nicotine exposure awaits further
exploration.
Finally, we turned our attention to host cell nAChRs. We focused on α7
nAChRs because of the availability of C57BL/6 mice with α7 nAChR knockout
mutations29. In the xenograft model, we found increased tumor progression in α7
nAChR knockout animals, which is consistent with our in vitro proliferation data
for α7 nAChR silencing in unstimulated cells. However, when we created animals
with double mutations in KRAS and α7 nAChRs to test spontaneous tumor
development, the number and size of lung tumors was similar to that in KRAS
mice with wildtype expression of α7 nAChRs. Together, these studies suggest
that host cell α7 nAChRs may not play critical roles in tumor development driven
by mutations, but may play a vital role in cancers driven by oncogenic
microenvironments.
Another explanation is that other nAChRs overcompensate when α7
nAChRs are absent. As stated before, in cultured tumor cells (this report) and in
lung fibroblasts (unpublished observations), absence of α7 nAChRs leads to
increased cellular proliferation.
In summary, our studies shed light into the differential roles that α4 and α7
nAChRs play in LLC cells when tested in vitro. Specifically, α4 nAChRs were
found to promote lung carcinoma cell migration and colony formation on soft
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agar. α4 nAChRs were also found to play a role in cisplatin-induced apoptosis.
α7 nAChRs appear to have little to no effect on these processes, but both
receptors seem to play roles in cellular proliferation at baseline in unstimulated
cells. However, studies in animals suggest that neither receptor in the tumor cell
is essential for tumor development, growth, and progression in vivo in the
absence of exogenous nicotine stimulation. Rather, our in vivo studies point to an
important role of these receptors, specifically the α7 nAChRs, in the host.
Together, our studies suggest that targeting one receptor alone might be
insufficient to inhibit tumor progression in vivo, while targeting multiple nAChRs
might prove more successful.

Further exploration of the differential roles of

nAChRs in both cancer cells and host cells, especially in humans, will
undoubtedly enhance our understanding of how they influence cancer and other
biological processes. This work is expected to better direct our efforts towards
the development of effective strategies for intervention in the setting of lung
cancer and other tumors.
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SUMMARY AND CONCLUSIONS

CAVEATS AND WEAKNESSES
Our main goal in this study was to determine if nAChRs played an important role
in the development and progression of lung cancer. Previous studies implicating
these receptors in the etiology of lung cancer utilized chemical antagonists in
their methodology, which are notorious for their off-target effects. While we
believe our approach using shRNA technology is more specific and targeted to
individual receptors, it is important to note that knocking down the expression of
one receptor could lead to a compensatory increase or decrease in the
expression of other nAChRs and/or other relevant molecules.
While our data suggest the α4 and α7 nAChRs may play little to no role,
individually, in lung cancer progression, our data utilizing knockout animals
suggest an important role of the α7 nAChR in the host. We are now in the
process of developing an α4 nAChR knockout animal to further study the role of
these receptors in the host. However, this study did not offer any insight into what
cells and mechanisms might be mediating these effects. A vast number of cell
types in the body express nAChRs, and so knockout animals could have a large
number of processes affected compared to wildtype animals. Additional studies
are needed to examine exactly what is causing these effects in the α7 nAChR
deficient animals.
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FUTURE WORK
The future directions described here will seek to address the questions that
remain unanswered, as well as new questions that have arisen, in our attempts
to better understand the role that nAChRs play in lung cancer development and
progression. Our data presented here suggest an important role for the host in
lung cancer progression. For our future studies, we thus chose to examine three
aspects of the host that we believe important in helping us better understand lung
cancer development and progression.

Role of host nAChRs
Amidst the perceived importance of host nAChRs in the etiology of lung
cancer, we hypothesize that activation of nAChRs in lung fibroblasts promotes an
oncogenic microenvironment that renders the host susceptible to lung cancer
development and progression. We will examine this by exposing animals
chronically with nicotine in their drinking water and then injecting them with LLC
cells and examining tumor development and metastases. Presumably, any
differences we observe will be through affects on the host. However, signaling
through nAChRs has been shown to affect a number of different host responses,
such as inflammation, alterations in the immune system, and angiogenesis. We
will also examine these processes and investigate what cells and mechanisms
are mediating these effects.
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Role of tumor cell-stromal interactions
Recent studies have implicated the tumor microenvironment as a new
chemotherapeutic target, by demonstrating the importance of tumor cell-stromal
interactions in tumor progression. However, the exact mechanisms of how tumor
cell-stromal interactions drive lung cancer progression remain undefined. We
suspect host fibroblasts represent an important component of the tumor
microenvironment that may help drive tumor progression. Consistent with the
latter, we found that human NSCLC cells show alterations in cell morphology,
increased proliferation, and increased colony formation on soft agar when
exposed to conditioned media harvested from IMR-90 lung fibroblasts.
Interestingly, the fibroblast-derived conditioned media also promoted tumor cell
resistance to cisplatin-induced apoptosis. We plan on investigating these
interactions further, performing in vivo studies, and determining exactly what
soluble factors are mediating these responses.

Role of aging in the etiology lung cancer
Cancer incidence is known to rise exponentially with age. This is thought
to be due to the accumulation of oncogenic mutations, as well as changes in the
tissue microenvironment. Consistent with this, we found that aged animals
showed greater metastases to the lung in our LLC model when compared to
young animals (Figures 10-12). We began to inquire into the mechanisms for
this observation. Dean Jones at Emory University, after testing hundreds of
healthy and diseased individuals, has recently shown that the physiological
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cysteine/cystine redox potential found in the plasma of healthy subjects is around
-80 mV. In subjects with disease, this redox potential may be oxidized to values
between -62 to -20 mV. Relevant to our proposal is the fact that aging is
associated with alterations in this mechanism. We have shown that this oxidative
stress can activate nAChRs, and lead to increased expression of extracellular
matrix proteins. We have also shown that aged lungs show alterations in the
expression of extracellular matrices. We thus hypothesize that aging, by
activation of nAChRs in the lung via oxidation of the cysteine/cystine redox
potential, promotes an oncogenic microenvironment that renders the host
susceptible to lung cancer development and progression. If this is true, we
deduce that we can prevent lung metastasis in old animals through dietary
interventions. Cysteine and cystine are derived from dietary sulfur amino acids
and Dean Jones has also shown that oxidation of the cysteine/cystine redox
potential could be mimicked in rodents exposed to a diet with low sulfur content,
while a diet with high sulfur content could reverse the effect30. Thus, we predict
that a diet with supplementation of sulfur can reverse the oncogenic
microenvironment observed in aged animals.
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Figure 10

Figure 10. Metastases in young versus old mice
Retrospective analysis of 6 in vivo experiments was performed. Each experiment
included WT C57BL/6 animals injected with WT LLC cells. Mice 3 months of age
and younger failed to develop metastases, while metastasis in mice after 7
months of age was almost consistently 100%.
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Figure 11

Figure 11. Old animals are more susceptible to lung cancer metastasis
Young (4 months, n=7) and old (19 months, n=7) WT C57BL/6 animals were
injected with 1x106 WT LLC cells into the hind flank. Tumor formation and size
were followed up to 2 weeks. A tumor size of ≥15mm in length or width was
established as the endpoint according to IACUC regulations. Mice were
sacrificed at 2 weeks and lungs harvested and processed for examination of
metastases. All animals developed tumors at the site of injection, with no
differences in size observed. 1/7 animals in the young group developed
metastases, while 6/7 animals in the old group developed metastases.
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Figure 12

Figure 12. Lung images of young versus old mice injected with LLC cells
Young (4 months, n=7) and old (19 months, n=7) WT C57BL/6 animals were
injected with 1x106 WT LLC cells into the hind flank. Tumor formation and size
were followed up to 2 weeks. A tumor size of ≥15mm in length or width was
established as the endpoint according to IACUC regulations. Mice were
sacrificed at 2 weeks and lungs harvested and processed for examination of
metastases.
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